Clinical Trial Update: Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a four-drug combination of sintilimab, bevacizumab, pemetrexed, and cisplatin for unresectable malignant peritoneal mesothelio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peritoneal Mesothelioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)
• Sintilimab (sintilimab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Malignant Peritoneal Mesothelioma, Advanced | Phase 2 | Status: RECRUITING